Puretech Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRTC. Needs to review the security of your connection before proceeding. Measures how much net income or profit is generated as a percentage of revenue.
Track sectors and industries performance, see top performing companies, and find news relevant to you. The interactive charting tool provides extensive upper and lower indicators, news and fundamental overlays, and comparison features. Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use. Register now to watch these stocks streaming on the ADVFN Monitor.
PureTech Announces Publication of Glyph™ Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release
A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. There are currently 287,796,585 shares in issue and the average daily traded volume is 220,055 shares. The market capitalisation the advantages & disadvantages of international bonds of Puretech Health Plc is £598,616,896.80. Any information that you receive via FT.com is at best delayed intraday data and not “real time”. Share price information may be rounded up/down and therefore not entirely accurate.
- Puretech Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRTC.
- Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness.
- Puretech Health Plc has a 4 week average price of 200p and a 12 week average price of 200p.
All of the underlying programs and platforms that resulted in the pipeline of therapeutic candidates are identified or discovered and then advanced by the PureTech team through key validation points based on insights in immunology and drug development. The Company’s wholly owned pipeline consists of various programs, including LYT-100, LYT-200, LYT-210, LYT-300, LYT-500, LYT-510, and LYT-503/IMB-150. Represents the company’s profit divided by the outstanding shares of its common stock.
While London South East do their best to maintain the high quality of the information displayed on this site, we cannot be held responsible for any loss due to incorrect information found here. This site does not provide investment advice, you should consult an Independent Financial Advisor that is authorised and regulated by the Financial Services Authority before making any investments. All content on FT.com is for your general information and use only and is not intended to address https://day-trading.info/ your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making any specific investment or other decisions. Take a deeper look into a company’s insider transactions by viewing director purchases and sales by individual directors. Puretech Health Plc has a 4 week average price of 200p and a 12 week average price of 200p.
The 1 year high share price is 300p while the 1 year low share price is currently 145.80p. Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.
PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan
FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions. It looks like a reverse takeover to me – I can’t see any logic in PRTC selling out as they have a cash runway to at least 2026 and cash/liquid assets worth more than the current mkt cap so everything else is in for free. Nektar need rescuing probably I am guessing but our management team have some serious explaining to do if they are going to get our shareholders to agree to this proposal.